



Companion Diagnostics: *Technologies and Markets*

March 2017

Robert Hunter

Report Code: BIO077C



Table of Contents

- Chapter 1: Introduction 1
 - Study Goals and Objectives..... 1
 - Reasons for Doing the Study..... 1
 - Scope of Report..... 1
 - Intended Audience..... 2
 - Methodology..... 2
 - Information Sources..... 2
 - Analyst's Credentials..... 4
 - Related BCC Research Reports..... 4
- Chapter 2: Summary and Highlights..... 6
- Chapter 3: Personalized Medicine Overview..... 10
 - Overview 10
 - 2015 Precision Medicine Initiative 12
 - Oncology as Major Driver 12
 - Potential for Personalized Medicine 12
 - Biomarkers 13
 - Companion Diagnostics Overview 15
 - General Application Categories 15
 - FDA Definition 16
 - Complementary Dx..... 16
 - FDA Cleared (510k) and Approved (PMA) Market..... 17
 - FDA Full CDx Designation 17
 - Beyond “FDA Designated CDx” 19
 - LDTs 27
 - Pharmaceutical-Diagnostic Deals..... 27
 - Company Types..... 27
 - In Vitro Diagnostics Companies..... 27
 - Molecular Diagnostics Industry 28
 - Companion Diagnostics Companies 30
 - Laboratory Test Services Companies 32
 - Biomarker Research Companies 32
 - Medical Centers..... 32
 - History of Companion Diagnostics..... 32
 - Regulatory Aspects 33
 - Key Companies..... 33
 - Cancer Market Segment 33
 - Technologies Overview 33
 - Reimbursement 34
 - Drivers of Adoption..... 34
 - Barriers to Adoption 35
 - Cost of CDx Development 36
 - CDx Regulatory Issues 36
 - FDA Route..... 36
 - Laboratory-Developed Tests Route..... 37
 - Choosing A Regulatory Pathway 37

Obstacles	38
Chapter 4: CDx Applications Other Than Cancer	40
Scope.....	40
Established Clinical Applications.....	41
Overview	41
Background on Clinical Genomics	41
Early Focus on Rare Diseases	41
Challenge of Rare Disease Clinical Trials	41
Cystic Fibrosis Experience	42
Driver for Laboratory-Developed Tests.....	42
Newborn Screening Panel	42
Data Aggregation and Management	43
Patient Bias vs Asymptomatic Screening	43
Cystic Fibrosis	43
CTFR Diagnostics	45
Next-Generation Sequencing Leadership.....	46
Pharmacogenomics	46
Pharmacogenomics Adoption	47
Current Successes in Pharmacogenomics.....	47
Warfarin	47
Simvastatin	48
Cancer Drugs	48
Liver Enzyme CYP2C19 and CYP2D6.....	50
Clopidigrel.....	51
Codeine.....	51
Human Leukocyte Antigen B	52
Carbamazepine.....	52
Azathioprine	53
Mental Health.....	53
Antidepressants.....	53
Serotonin.....	54
Catechol-O-Methyltransferase.....	54
Pharmacokinetic and Pharmacodynamic Genes.....	54
Challenges and Future Directions	55
Validation	55
Infectious Disease CDx.....	56
HIV Statistics and Healthcare Cost	56
HIV Drug Market.....	56
Representative Drug Companies	57
ViiV Healthcare	58
HIV Drug-Resistance Tests.....	58
Tropism for HIV Assay	59
Competitors of Trofile Assay.....	60
Hypersensitivity Test HLA-B 5701	60
Applications in Vaccine Development	61
Partnerships and Collaborations for Companion Diagnostics for Infectious Diseases	61
Other Applications Beyond HIV	62
Hepatitis C Genetic Test for IL28B.....	62
Market Forecast.....	62

Chapter 5: FDA Designated CDx — Cancer	64
Overview	64
Overview of Cancer.....	65
Background: Docetaxel Chemotherapy.....	65
Breast Cancer	65
Overview	65
HER2-positive Breast Cancer	65
Herceptin (Trastuzumab): Roche (Genentech).....	66
HercepTest (Dako Now Part of Agilent)	66
Kadcyla: Roche (Genentech).....	67
Perjeta: Roche (Genentech).....	67
CDx for Herceptin.....	67
Manufacturers of HER2 Assays	68
Dako Corp – IHC Antibody.....	68
FISH, PathVysion (Abbott Laboratories).....	69
Life Technologies (Thermo Fisher)	69
Others.....	69
Other HER2 Drugs: Tykerb (Lapatinib), Novartis.....	70
HER2 for Other Cancers.....	70
Unmet Needs.....	70
Epidermal Growth Factor Receptor	71
Non-Small-Cell Lung Cancer	71
Erbix for Non-Small-Cell Lung Cancer	72
Tarceva (Erlotinib): Roche/Astellas.....	72
Iressa (Gefitinib): AstraZeneca.....	73
Gilotrif (Afatinib): Boehringer Ingelheim	73
T790M Mutation Resistance	74
Tagrisso (Osimertinib or AZD9291, AstraZeneca).....	74
Cobas EGFR Mutation Test v2: Roche.....	74
Other Drugs for Lung Cancer	74
CDx: Therascreen (PCR)	74
Colorectal Cancer	75
Background: Avastin: Roche (Genentech).....	75
CDx: IHC and FISH	75
Vectibix (Panitumumab): Amgen	76
CDx: EGFR PharmDx Kit (Dako).....	76
Erbix (Cetuximab): Eli Lilly (ImClone)	76
Excluding KRAS Mutations	76
Head and Neck Cancers.....	76
EGFR CDx: Leaders and Followers.....	77
Differences in the U.S. and EU	77
KRAS Market	78
KRAS Leaders.....	78
Anaplastic Lymphoma Receptor Tyrosine Kinase	79
Xalkori (Crizotinib), Pfizer’s Approved NSCLC Therapy	79
CDx: Abbott Vysis FISH for Xalkori.....	80
CDx: Ventana	80
ROS-1.....	81
Ibrance	81
BRAF.....	82

Zelboraf (Vemurafenib) Melanoma: Genentech (Roche)	82
Cobas 4800 BRAF V600 Mutation Test.....	82
Mekinist (Trametinib) in Combination with Tafinlar (Dabrafenib): Novartis	82
THxID-BRAF Kit (bioMérieux Inc.).....	83
Ventana BRAF V600 (VE1) Antibody	83
BRAF Future Research	84
BCR-ABL for Chronic Myelogenous Leukemia	84
Overview	84
Chronic Myelogenous Leukemia	85
BCR-ABL.....	85
Gleevec.....	86
Tests for Gleevec Treatment.....	86
Gastrointestinal Stromal Tumor.....	87
CDx: DakoCytomation’s c-Kit (9.7) pharmDx S2.....	87
ASM and MDS/MPD S2	87
CDx: LDTs by ARUP Laboratories.....	87
BRCA1/2	88
Overview	88
CDx: BRACAnalysis (Myriad Genetics).....	88
Immune Checkpoint Inhibitors: Keytruda and Opdivo	89
PD-1 and PD-L1 Inhibitors: Protein Markers.....	89
CDx: PD-L1 IHC 22C3 pharmDx (Dako)	89
Market Forecast.....	89
Chapter 6: Current Techniques, Technologies and Market Structures	91
Overview	91
Foundation: Tissue Dx- Histopathology	91
Major Types Of Tissue Diagnostics	91
Hematoxylin & Eosin (H&E).....	91
Immunohistochemistry (IHC)	92
In situ Hybridization (ISH).....	92
In Practice Used Together.....	92
Example: Ventana (Roche)	92
Tissue Dx Market.....	92
Driver: FFPE Compatibility.....	93
Digital Pathology and Quantitative Immunostaining.....	94
Future Digital Transformation.....	95
Imaging.....	95
Cell Dx: Immunohistochemistry, In Situ Hybridization, DNA, and Quantitative Polymerase Chain Reaction	95
Protein-Based	95
Chromosome-Based	96
DNA-Based.....	96
mRNA-Based.....	96
microRNA-Based.....	96
Metabolite-Based	96
Imaging-Based	96
Immunohistochemistry (IHC).....	96
Example: Dako (Now Part of Agilent).....	97
Practical Application.....	97
Tissue Context is Key.....	98

Challenges: Quantification	98
Newer IHC: Quantitative Immunofluorescence (QIF)	98
Future Perspectives	99
Fluorescent In Situ Hybridization	99
Example: Abbott Molecular Diagnostics	99
FISH vs IHC	100
Chromogenic In Situ Hybridization	100
Polymerase Chain Reaction	101
Pros and Cons	102
Discussion	103
Gene Sequencing	103
Overview	103
Functional Genomics	104
Somatic vs Germline Sequencing	104
Tools Used in Functional Genomics	104
History of DNA Sequencing	105
Overview of DNA Sequencing	105
RNA Sequencing	106
Increasing Share	107
Hereditary Cancer Market Leader	108
Trends	108
Current Tests Mostly Single-Target	108
Future: More Multi-gene Panels	108
Novel Panels Drive Growth and Complexity	109
Most Common Genes Included in Myriad of Products	109
Other Sequencing Approaches	109
Other Technologies	110
Recap	111
NGS as a Growth Driver	112
NGS Poised to Dominate	112
Envisioning NGS Panels	112
Enabling New Paradigm: Dx Drives Rx	113
Primer on NGS Platforms	113
FDA-cleared MiSeqDx	113
Clinical Challenges for NGS	113
Standardization Challenges for NGS	114
LDTs: Key Market Structure	114
Background	114
LDT Share of CDx	115
NGS Driving LDTs	115
Regulatory Drivers	115
Stricter Regulation of LDTs	115
Market Response	116
Implications	116
NGS Driving Liquid Biopsy Technology	117
Market Forecast	117
Chapter 7: Not FDA Required	119
Overview	119
FDA-Approved Kits or Tests: 510(k) and PMA	119
Laboratory-developed Tests	120

LDT Share of CDx	120
LDT Advantages	120
Innovation: Panels	120
LDT Industry Structure	121
Regulatory Outlook and Impact	121
Next-Gen Industry Leadership.....	121
Key Context of Breast Cancer	121
Breast Cancer Industry.....	122
Overview of Breast Cancer	122
Breast Cancer Tests	123
Drug Pipeline	123
King of Prognostic and Predictive.....	123
Tests to Guide Treatment.....	124
Next-Gen Dx Drivers	124
Disease Overview	124
Classification of Breast Cancer	125
Breast Cancer Evaluation	125
Stage of Disease	126
Ductal Carcinoma In Situ Recurrence	127
Oncotype DX Breast Cancer Test.....	127
Hormone Sensitivity.....	128
Estrogen Receptor	128
HER2 Type	128
Triple Negative	129
Causes, Incidence and Risk Factors	129
Pathophysiology	130
ER Positive	131
Metastatic Breast Cancer	131
Prevention.....	131
Overdiagnosis.....	131
Treatment	132
Overview	132
Cancer Treatment: Local or Systemic.....	132
Driven by Stage.....	132
Treatment Guidelines.....	133
Prognosis after Treatment	133
Hormone Therapy	134
Aromatase Inhibitors.....	136
Traditional Drugs.....	139
Overview	139
Chemotherapy.....	139
Drugs to Control Side Effects of Breast Cancer Treatment.....	139
Platinum-based Chemotherapy	140
Adjuvant and Neo-Adjuvant Therapy.....	140
List of FDA-Approved Drugs	140
Targeted Therapies for Breast Cancer	142
Herceptin (Trastuzumab)	142
Avastin	144
Kadcyla: Roche (Genentech)	144
Perjeta: Roche (Genentech)	145
Tykerb (Lapatinib): Novartis	145

HER2 for Other Cancers.....	146
Unmet Needs.....	146
CDx for Herceptin.....	146
Emerging Therapies	147
Triple Negative Breast Cancer	147
PARP Inhibitors.....	148
BRCA Targeted Olaparib.....	148
Diagnosis and Trends	148
Screening.....	150
Early Imaging Tests.....	150
Mammography.....	150
Magnetic Resonance Imaging of the Breast.....	152
Biopsy.....	153
Fine Needle Aspiration Biopsy	153
Core Needle Biopsy	154
Vacuum-Assisted Biopsies.....	154
Surgical (Open) Biopsy.....	154
Laboratory Examination.....	155
Grades of Breast Cancer.....	155
Market Drivers	156
Tissue Diagnostics	156
Response to Chemotherapy.....	158
Genomics Revolution	161
DNA Repair Pathways.....	163
Treatment Selection.....	166
Autoimmune Progression (Future).....	168
Current Commercial Status.....	169
Technologies	169
Overview	169
Immunohistochemical.....	169
Fluorescent In Situ Hybridization	170
Genomic	171
Leading Breast Cancer Genomic Tests	175
Other Genomic Tests.....	176
Others.....	177
Mostly LDTs	178
Cancer Prediction.....	178
Example: BRCA (Myriad)	178
Early Detection/Screening Tests.....	179
Risk Assessment Tests.....	180
Discussion.....	182
Lab-Developed Tests: Outlook.....	182
Background.....	182
Stricter Regulation of Lab-Developed Tests	183
Market Response.....	184
Implications	184
Reimbursement.....	184
Market Forecast.....	185
Chapter 8: Emerging Liquid Biopsy Market	187
Overview	187

Phases of Adoption	187
Limitations of Current Disease Diagnosis	187
Limitations of Minimally Invasive Methods	187
Unmet Need: Lung Cancer	188
Example: Roche Diagnostics.....	189
Example: GeneStrat and VeriStrat by Biodesix	190
Unmet Need: Bladder Cancer.....	190
Example: Oncocyte Technology	191
Unmet Need: Thyroid Cancer	191
Screening Opportunities.....	192
Example: Lung Cancer Complement to CT Scanning.....	192
Example: Oncocyte.....	193
Huge Increase in Screening Opportunity	194
Technology Overview	195
Earlier Approaches	196
Other Companies.....	197
Later Approaches	198
Whole Cell Approach.....	198
Cell-free DNA and Circulating Tumor DNA	199
Additional Applications	201
KRAS Pancreatic: Small but Clearly Defined.....	204
NSCLC: Secondary EGFR Mutation	205
KRAS and Response to Anti-EGFR Drugs	205
PD-L1 in Immuno-oncology	206
Example: Biocept.....	206
Exosomes.....	206
Pancreatic Cancer.....	207
Exosomes: Experiment July 2015.....	208
Market Drivers.....	208
Shortcomings.....	209
Unmet: Early Detection	209
Noninvasive Prenatal Testing as Guide for Liquid Biopsy	209
Overview	209
From Noninvasive Prenatal Testing to Maternal Cancers.....	210
Noninvasive Prenatal Testing Accelerates Cell-Free DNA.....	210
Reimbursement.....	211
Strength of Noninvasive Prenatal Testing Companies	212
Recent Venture Funding.....	212
Noninvasive Prenatal Testing Tests and Leading Companies	213
Patent Pooling	214
High Risk Only, So Far	215
Noninvasive Prenatal Testing Market Outlook	215
Noninvasive Prenatal Testing Plans for Liquid Biopsy.....	215
Status of Liquid Biopsy Market.....	216
Regulatory Backdrop	218
Technical Issues.....	219
Future Outlook	219
Market Forecast.....	220
Chapter 9: Universal CDx	222
Overview	222

Drivers	222
Rapid Increase in Targeted Therapies	222
Limited and Poor Tissue Quality.....	223
Physician Difficulty with Complexity	223
Off-Label Prescription.....	223
Difficulty Integrating into Clinical Practice	224
Increasing Focus on Community Practices	224
Regulatory Challenges	224
Technology Disruption	225
Economic Disincentives	225
Biomarker Challenges.....	225
Progress from Proteomics.....	225
Metabolomics Advantage	227
Increasing Molecular and Genomics Driven.....	228
Existing Single Marker and Gene Panel Approaches.....	228
Unmet Need for Whole Genome Sequencing	229
Example: NantHealth-GPS Cancer.....	229
Challenges to Adoption of Comprehensive Molecular Analysis	229
Examples and Initial Adoption.....	230
Market Forecast.....	236
Chapter 10: Future Applications: Cardiovascular and Metabolic Disease.....	238
Overview	238
Applications.....	238
Planned Myocardial Ischemia and Infarction	239
Exercise Stress Testing	239
Alcohol Septal Ablation.....	239
Nitric Oxide Metabolic Pathway	240
Anthracycline-induced Cardiotoxicity.....	240
Atrial Fibrillation	240
Pulmonary Arterial Hypertension	241
Pulmonary Hypertension as Mitochondria Dysfunction.....	242
Pulmonary Hypertension and Insulin Resistance	242
Atherosclerosis Risk	242
Lipid Profiles.....	242
Cholesterol.....	242
Particles.....	243
Cholesterol Testing Clinical Uses	243
Statins	244
Possible Adverse Drug Reactions.....	244
Serum Markers.....	244
Statin Dose Marker	245
Coadministration	245
Metabolization Differences	245
Genetic Variability.....	245
Lipid Profile	246
Beyond Statins to Multimarker Approach	246
Jupiter Trial.....	246
Jupiter Expands Statin Use	247
Jupiter Also Raises Diabetes Risk	247
Guidelines	247

Systemic and Vascular Inflammation.....	248
High-Sensitivity C-Reactive Protein.....	248
Myeloperoxidase	248
Lipoprotein-Associated Phospholipase-A2	248
Advanced Lipid Testing	249
Apolipoprotein B and A1 (ApoA1).....	249
Small-Dense LDL	249
Lipoprotein (a).....	249
HDL2b	249
Particle Type.....	250
Companies Offering Advanced Lipid Testing	250
Liposcale Test.....	250
Primary Care Physicians	250
Cleveland HeartLab.....	250
Non-fasting Triglycerides	251
Metabolomic Applications.....	251
Lipidomics	251
Choline Metabolism	251
Acylcarnitines.....	252
Trimethylamine N-oxide	252
Microflora-derived Choline Metabolites	253
Link with Gut Microflora	253
Diabetes and Prediabetes	253
Insulin Resistance.....	253
Link with Obesity Not Conclusive.....	254
Tools to Detect Insulin Resistance	254
Companies Offering Insulin-Resistance Testing.....	255
Other Insulin-Resistance Testing	255
Branched-Chain Amino Acids: Insulin Resistance via Exercise Stress Testing.....	255
Branched-Chain Amino Acids and Gastric Bypass.....	256
Liver Diseases.....	257
Methylation Deficiency.....	257
Folate Deficiency.....	257
Clinical Liver Disease	258
Diagnosis	259
Treatment.....	259
Research	260
Progress on Non-Alcoholic Fatty Liver Disease	260
One Way Liver Genomics	260
European Association for the Study of the Liver.....	260
Applications in Liver Research.....	261
Liver Metabolism Overview	261
Liver Function and Structure	261
Drug-Induced Liver Injury	264
Example: Kiyatec	265
Liver Inflammation Models	265
Example: Hepregen	266
Liver Regeneration	266
Commercial Considerations.....	266
Laboratory-Developed Tests	266
Market Forecast.....	267

Chapter 11: Representative Acquisitions and Company Profiles 269

About BCC Research 341

About BCC Research..... 342

BCC Membership 342

BCC Custom Research 342

List of Tables

Summary Table Global Companion Diagnostics Market, by Category, Through 2021 (\$ Millions).....	7
Table 1 Novel New Drug Approvals, 2011–2015	10
Table 2 Novel New Drugs and Percentage Personalized	11
Table 3 2015 Newly Approved Medicines	11
Table 4 Potential Markets for Personalized Medicine (\$ Billions)	13
Table 5 Examples of Personalized Medicine Tests	13
Table 6 Biomarker Applications (% of R&D Applications).....	14
Table 7 Biomarkers Used in Companion Diagnostics.....	14
Table 8 FDA Designated CDx.....	17
Table 9 Partial List of FDA Cleared and Approved Tests for CDx Applications	19
Table 10 Partial List of Biomarkers for FDA Cleared and Approved CDx Tests.....	21
Table 11 Cancer Biomarkers Implemented as FDA CDx VS FDA Cleared/Approved VS LDTs	26
Table 12 Total Tests Cleared or Approved by FDA Since 2003	26
Table 13 Market Shares of Major In Vitro Diagnostics Companies (%)	28
Table 14 Molecular Diagnostics Companies and Representative Revenue, 2013 (\$ Millions).....	29
Table 15 Market Share of MDX Sectors (%).....	30
Table 16 Representative List of CDx Companies	30
Table 17 Pricing for Common Cancer Drugs (\$).....	34
Table 18 Nine Factors That Influence Companion Diagnostic Development and Adoption	35
Table 19 Established and Emerging CDx Applications	40
Table 20 Tests for Cystic Fibrosis	44
Table 21 G6PD Testing Companies	50
Table 22 CYP Sensitive Drugs	51
Table 23 Global Human Immunodeficiency Virus Drug Market, 2013 and 2018 (\$ Billions)	57
Table 24 Companion Diagnostic Tests on the Market for Infectious Diseases, 2013.....	61
Table 25 Partnerships in the Field of Companion Diagnostics for Infectious Diseases Between Diagnostics and Pharmaceutical Companies, 2009–2012	61
Table 26 Global Market for FDA Cleared/Approved Applications Other Than Cancer, by Category, Through 2021 (\$ Millions).....	62
Table 27 FDA Designated CDx by Rx	64
Table 28 HER2 CDx Tests FDA Required for Herceptin	68
Table 29 FDA Required EGFR CDx Tests.....	71
Table 30 FDA Required KRAS CDx Tests.....	78
Table 31 FDA Required ALK CDx Tests.....	81
Table 32 FDA Required BRAF CDx Tests.....	83
Table 33 FDA Required CDx Tests for Gleevec.....	84
Table 34 FDA Required BRAC1/2 CDx Tests.....	88
Table 35 Global Market for FDA Cleared/Approved Cancer Applications, by Category, Through 2021 (\$ Millions)	89
Table 36 Advantages and Disadvantages of the Most Common Techniques for Companion Diagnostics, 2013	102
Table 37 Global Market for FDA Cleared/Approved Cancer Applications, by Category, Through 2021 (\$ Millions)	117
Table 38 Breast Cancer Stages and Specific Diagnosis	126
Table 39 SEER Summary Stage System for Breast Cancer	126
Table 40 Breast Cancer Stages.....	133
Table 41 Hormone Therapy Types for Breast Cancer	134

Table 42 Hormone Therapy Drugs for Breast Cancer	135
Table 43 Aromatase Inhibitors for Treating Breast Cancer	136
Table 44 Chemotherapy Drugs for Treating Breast Cancer	139
Table 45 Drugs Approved to Treat Breast Cancer	141
Table 46 Targeted Therapeutics for Breast Cancer	144
Table 47 HER2 CDx Tests FDA Required for Herceptin	147
Table 48 Recurrence Rates at Five Years in Patients with Lymph Nodes that are Positive for Cancer (%)	149
Table 49 Five-Year Survival Rates Correlated with Tumor Stage.....	149
Table 50 Imaging Tests That Determine if Breast Cancer has Spread	153
Table 51 Grades of Breast Cancer.....	155
Table 52 Myriad Genetics/CDx Partnerships	165
Table 53 IHC and FISH HER2 Tests	171
Table 54 Genetic Tests for Breast Cancer Treatment.....	172
Table 55 Leading Breast Cancer Genomic Tests	174
Table 56 Gene Expression Profiling Tests	177
Table 57 Laboratories Offering BRCA Tests	179
Table 58 Next-Generation Breast Cancer Tests	180
Table 59 Laboratory-Developed Test Providers.....	183
Table 60 Global Market for LDT Cancer Applications, by Category, Through 2021 (\$ Millions)	185
Table 61 Advantages of Liquid Biopsy	189
Table 62 CTC Phenotype Criteria Used by CellSearch.....	197
Table 63 Noninvasive Prenatal Testing Adoption Cycle.....	211
Table 64 Genetic Testing Companies Market Shares (%)	212
Table 65 Recent Venture Funding of Liquid Biopsy Companies	212
Table 66 Global Market for Liquid Biopsy Technology, Through 2021 (\$ Millions).....	220
Table 67 Universal CDx Companies.....	222
Table 68 Global Market for Decision Support Tools from Universal CDx Developers, by Category, Through 2021 (\$ Millions).....	236
Table 69 Global Metabolomics Market, by Biomarker, Through 2020 (\$ Millions)	267
Table 70 Representative Acquisitions.....	269

List of Figures

Summary Figure Global Companion Diagnostics Market, by Category, 2015–2021 (\$ Millions)..... 8



About BCC Research

About BCC Research

With our unparalleled 45-year history, BCC Research provides comprehensive analysis of global market sizing, forecasting and industry intelligence, covering markets where advances in science and technology are improving the quality, standard and sustainability of businesses, economies and lives.

BCC Membership

From market sizing and forecasts, to opportunity assessments and competitive analyses, our ever-expanding library gives you the data, insights and intelligence required to ensure your project is a success. Members benefit from ongoing, unlimited access to the category or collections of their choice, and most membership packages pay for themselves within two to three reports being accessed.

Did you buy this report? You may qualify to apply your purchase price towards a full membership. Call 866/285-7215 or email info@bccresearch.com to request a demo.

BCC Custom Research

Our experts provide custom research projects to those working to identify new markets, introduce new products, validate existing market share, analyze competition and assess the potential for products to impact existing markets. With impressive academic credentials and broad and deep knowledge of global industrial markets, our independent analysts and consultants develop the facts, figures, analysis and assessments to inform the decisions that will move your company ahead. Confidential inquiries to: custom@bccresearch.com or 781-205-2429.

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and is of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it be considered as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

ISBN: 1-62296-447-0
March 2017